Date: 2014-09-15
Type of information: Grant
Company: Morphosys (Germany)
Investors: German Ministry of Education and Research (BMBF) (Germany)
Amount: up to € 1 million
Funding type: grant
Planned used: The funding will support Morphosys in developing Ylanthia antibodies against two undisclosed G protein-coupled receptors (GPCRs). The grant will cover all necessary steps involved in the early drug development stages and will run for two years. The superfamily of G protein-coupled receptors is the single largest and most important family of drug targets. Receptors of this class play a central role in many biological processes and are linked to a wide range of diseases. However, due to immense technical difficulties in generating selective and potent antibodies against this target class, only one GPCR-targeted antibody drug has been approved so far. With the help of its advanced proprietary technologies, first and foremost its next-generation antibody platform Ylanthia, MorphoSys is able to exploit the full potential of therapeutic antibodies against GPCRs.
Others: * On September 15, 2014, MorphoSys announced the receipt of a grant of up to € 1 million from the German Federal Ministry of Education and Research (BMBF), comprising funding for two of its therapeutic antibody programs.
Therapeutic area:
